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Abstract
Skeletal tumour burden is a biomarker of prognosis and survival in cancer 
patients. This study proposes a novel method based on the linear quadratic 
model to predict the reduction in metastatic tumour burden as a function of the 
absorbed doses delivered from molecular radiotherapy treatments.
The range of absorbed doses necessary to eradicate all the bone lesions and 
to reduce the metastatic burden was investigated in a cohort of 22 patients with 
bone metastases from castration-resistant prostate cancer. A metastatic burden 
reduction curve was generated for each patient, which predicts the reduction 
in metastatic burden as a function of the patient mean absorbed dose, defined 
as the mean of all the lesion absorbed doses in any given patient. In the patient 
cohort studied, the median of the patient mean absorbed dose predicted 
to  reduce the metastatic burden by 50% was 89 Gy (interquartile range: 
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83–105 Gy), whilst a median of 183 Gy (interquartile range: 107–247 Gy) 
was found necessary to eradicate all metastases in a given patient. The 
absorbed dose required to eradicate all the lesions was strongly correlated 
with the variability of the absorbed doses delivered to multiple lesions in a 
given patient (r  =  0.98, P  <  0.0001). The metastatic burden reduction curves 
showed a potential large reduction in metastatic burden for a small increase in 
absorbed dose in 91% of patients.
The results indicate the range of absorbed doses required to potentially 
obtain a significant survival benefit. The metastatic burden reduction method 
provides a simple tool that could be used in routine clinical practice for 
patient selection and to indicate the required administered activity to achieve 
a predicted patient mean absorbed dose and reduction in metastatic tumour 
burden.
Keywords: radiobiology, dosimetry, radiopharmaceuticals, bone metastases, 
prostate cancer, molecular radiotherapy
(Some figures may appear in colour only in the online journal)
Introduction
Bone metastases are a common indicator of distant relapse from various cancers, in particular 
those arising in the prostate, lung and breast (Mundy 2002). They can lead to complications 
such as severe pain, pathological fractures and spinal cord compression; which significantly 
decrease patient quality of life and shorten survival (Coleman 2001). Current treatments for 
patients with bone metastases are primarily palliative, including the use of analgesics, exter-
nal beam radiotherapy, bisphosphonates, chemotherapy or molecular radiotherapy with bone-
seeking radiopharmaceuticals (Coleman 2001).
Radiation therapy is an effective treatment modality for bone pain palliation and evidence 
has shown equal pain relief for single and multi-fraction treatments, providing pain relief 
in up to 80% of patients (Chow et al 2012). The biological effects of radiation in a curative 
cancer treatment are not as relevant to a palliative setting, as low absorbed doses are used for 
bone pain palliation in contrast to the higher levels of radiation required for tumour eradica-
tion. However, recent treatment advances in stereotactic body radiation therapy (SBRT) have 
enabled the safe delivery of ablative radiation doses with minimal normal tissue toxicity to 
patients with low number of metastases and oligometastatic disease (Tree et al 2013, Saluja 
et al 2016). Molecular radiotherapy with bone-seeking radiopharmaceuticals can also poten-
tially deliver high absorbed doses to the bone lesions cells whilst minimising bone marrow tox-
icity (Goyal and Antonarakis 2012). A survival benefit has been observed for 89Sr-dichloride 
following 6 weekly cycles of doxorubicin as compared to chemotherapy alone in patients 
with metastatic castration-resistant prostate cancer (mCRPC) (Tu et al 2001). More recently, 
223Ra-dichloride was shown to improve survival against placebo (Parker et al 2013), introduc-
ing a shift in patient management from pain palliation to prolonged survival (Liepe and Shinto 
2016). The prospect of further significant improvements in survival is underlined by the lim-
ited haematological toxicity resulting from current treatments (Bruland et  al 2006, Parker 
et  al 2013) and the practicality of high activity administrations in combination with stem 
cell transplantation (O’Sullivan et al 2002, O’Sullivan 2006). This indicates the potential for 
more aggressive administrations if a personalised treatment planning approach is used. Such 
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treatments require quantification of image data to facilitate patient-specific dosimetry and the 
development of models to explain the clinical significance of the calculated absorbed doses.
Available radiobiological models of metastatic control provide the probability of eradicat-
ing all the metastases in a given patient (Bernhardt et al 2003, 2004). Numerous studies have 
shown that the skeletal tumour burden (Soloway et al 1988, Dennis et al 2012, Denis-Bacelar 
et al 2017) is closely related to overall survival. Therefore, a more clinically realistic measure 
of metastatic control would be to consider the reduction in metastatic burden and prevention 
of spread of the disease rather than complete cure. The aim of this study was to propose a new 
method to predict the decrease of metastatic burden for any given patient-specific distribu-
tion of lesion absorbed doses following radiotherapy. The application of this methodology in 
clinical practice was assessed using available clinical data from patients with mCRPC, which 
reveals a new framework within which the potential for prolonged survival and metastatic 
tumour burden reduction could be explored.
Material and methods
Ionising radiation induces DNA damage mainly via single and double-strand breaks, which 
can lead to cell death. The linear quadratic (LQ) model is commonly used to describe cell kill 
from tissue irradiation (Dale 1985), where the cell survival fraction is given as:
( ) ( )= α β− +DSF e ,D GD2 (1)
where α (Gy−1) and β (Gy−2) are tissue dependent constants used to describe the probability 
of cell death by double-strand breaks and by two consecutive single-strand breaks to occur 
respectively. Repopulation effects were not considered.
Considerably lower absorbed dose rates are delivered in molecular radiotherapy as com-
pared to external beam radiotherapy; therefore the contribution from the quadratic component 
is smaller, as many of the single-strand breaks are repaired during irradiation. To account 
for the repair of sub-lethal damage from protracted irradiation during a time T, the quad-
ratic comp onent of the LQ model is modified by the Lea–Catcheside factor (G) (Millar 1991, 
Gerweck et al 2006):
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For molecular radiotherapy, with a mono-exponentially decreasing absorbed dose rate which 
is allowed to decay (T  →  ∞):
( ) λ
λ µ
∞ =
+
G , (3)
where λ is the effective decay constant which accounts for the physical and biological half-
lives of a given radiopharmaceutical, and μ is the repair rate constant. Typical sub-lethal dam-
age repair half-times range between 16 min and 3 h (Dale and Carabe-Fernandez 2005).
The biological effective dose (BED) accounts for the effects of the absorbed dose rate and 
the radiosensitivity and repair capacity of the considered tissue (Fowler 1989):
( )
( )α
λ
λ µ
= − = +
+ α β
⎛
⎝
⎜⎜
⎞
⎠
⎟⎟D DBED ln SF 1 , (4)
where the α/β ratio quantifies the radiosensitivity of a given tissue to changes in fractionation 
and Dλ is the initial absorbed dose rate of the radiopharmaceutical. Typical ratios for tumours 
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and early-reacting tissues including the bone marrow are 10 Gy, whilst late-responding tis-
sues show ratios of 2–5 Gy (Dale 2004). Prostate cancer is an exception, where most studies 
indicate low ratios of about 1–5 Gy (Brenner and Hall 1999, Fowler et al 2001, Wang et al 
2003, Oliveira et al 2012, Dearnaley et al 2016). An average effective half-life of 62 h was 
used (Graham et al 1999).
From the LQ model and considering Poisson statistics, the tumour control probability 
(TCP) expresses the probability of killing all clonogenic cells (N0) in a given bone lesion:
( ) ( ( ))ρ α= − × = − × −N VTCP exp SF exp exp BED ,0 c (5)
where ρc is the clonogenic cell density and V is the tumour volume.
The absorbed doses required to obtain a TCP of 0.95 depend on the radiobiological param-
eters used, however these are not known for radionuclides and bone lesions from prostate 
cancer. The results of this study are based on parameters corresponding to prostate cancer 
cells, with a clonogenic cell density of 3 · 106 cm−3, α/β of 3.1 Gy, α of 0.15 Gy−1 and repair 
constant μ of 0.46 h−1 (Wang et al 2003).
The metastatic control probability model
The metastatic control probability (MCP) model (Bernhardt et al 2003, 2004), has been previ-
ously used in molecular radiotherapy (Elgqvist et al 2010, Walrand et al 2012). In the context 
of skeletal metastases, it provides the probability of eradicating all the bone lesions in a given 
patient and it is defined as the product of the N individual lesion TCPs:
Π=
=
MCP TCP.
i
N
1
 (6)
The metastatic burden reduction model
A new framework for treatment planning is proposed, where the decrease in metastatic tumour 
burden is predicted as a function of the absorbed doses delivered to multiple bone lesions. If 
the patient mean absorbed dose (PMAD) is defined as the mean of N lesion absorbed doses 
in any given patient ( /= ∑ = D NPMAD iN i0 ), the metastatic burden reduction (MBR) following 
treatment is calculated as:
( ) ( )= − ∑ ×= v k D
V
MBR PMAD 1 ,i
N
i i i0 (7)
where = ∑ =V vi
N
i0  is the metastatic burden at baseline calculated as the sum of the volumes for 
N lesions of volume vi, and ( )
( )
( ) ⩾=
<⎧⎨⎩k D
TCP D
TCP D
1, 0.95
0, 0.95i i
i
i
 is a binary parameter that describes 
the eradicated (k  =  0) or non-eradicated (k  =  1) status of the ith lesion for a given lesion 
absorbed dose Di. The MBR ranges from 0 (no metastases have been eradicated) to 1 (all 
metastases have been eradicated).
Application to clinical data
Clinical data were obtained from 22 patients with CRPC metastatic to bone treated with a 
fixed administered activity of 5 GBq of 186Re-HEDP and with peripheral blood stem cell 
transplant support during a phase II clinical trial (O’Sullivan 2006). All patients provided 
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written informed consent to take part in the trials, which were approved by the Royal Marsden 
NHS Trust and The Institute of Cancer Research Ethics committee. Bone lesion dosimetry and 
skeletal metastatic tumour burden calculations were performed from quantitative sequential 
SPECT imaging as part of a previous study (Denis-Bacelar et al 2017). The delivered patient 
mean absorbed dose (PMADdelivered) was defined as the mean of the absorbed doses delivered 
to all lesions in any given patient. The relative distribution of lesion absorbed doses and the 
lesion volumes were used as the basis for the radiobiology calculations.
Calculations of the TCP were performed under the assumption of uniform absorbed dose 
distributions within the bone lesion and uniform radiosensitivity and clonogenic density 
across lesions and patients. The patient mean absorbed dose necessary to eradicate all the 
bone lesions within a patient (PMADMCP=0.95) was obtained by iteratively scaling the relative 
distribution of absorbed doses delivered to the lesions in a given patient by a target dose scal-
ing factor until MCP  =  0.95.
To assess the impact of the degree of absorbed dose variability between lesions upon the 
PMADMCP=0.95, different measures of variability were considered; including the range, vari-
ance, standard deviation, coefficient of variation and the range scaled by the minimum value.
The patient mean absorbed dose at which the metastatic tumour reduction is 100% 
approaches PMADMCP=0.95. Metastatic tumour reduction curves were obtained for a range of 
patient mean absorbed doses derived from scaling the relative distribution of absorbed doses 
delivered to the lesions for all patients. The patient mean absorbed dose required to decrease 
the metastatic tumour burden by 50% (PMADMBR=0.5) was calculated for each patient.
To assess the impact of the cut-off probability on the metastatic control and metastatic bur-
den reduction, the calculations were also performed for values of 0.9 and 0.99. The effect of 
an α parameter of 0.25 Gy−1 to represent metastatic lesions less radio-resistant than prostate 
cancer cells was also characterised.
Comparison between predicted and delivered absorbed doses
The predicted PMADMCP=0.95 and PMADMBR=0.5 values for the 22 patients were compared 
with the PMADdelivered from 5 GBq of 186Re-HEDP. Follow-up imaging was not available to 
determine the actual metastatic burden reduction following treatment.
Statistical considerations
Median and interquartile range (IQR) were used to describe continuous variables. Pearson’s 
correlation coefficients were used to quantify the degree to which two variables are related and 
regression analysis was used to identify relationships between variables. Two-sided P-values 
below 0.05 were considered significant.
Results
The metastatic control probability model
A median PMADMCP=0.95 of 183 Gy (IQR: 107–247 Gy) was obtained across the 22 patients. 
For cut-offs of 0.9 and 0.99 the PMAD median values of 178 Gy (IQR: 104–241 Gy) and 193 
Gy (IQR: 113–260 Gy) were obtained respectively. An α parameter of 0.25 Gy−1 reduced the 
PMADMCP=0.95 by 32% on average, with a median of 125 Gy (IQR: 73–169 Gy). Figure 1(a) 
shows a strong negative correlation and power relationship between the target dose scaling 
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factor and the minimum lesion absorbed dose (r  =  −0.89, P  <  0.0001). This indicates the 
strong influence of the minimum absorbed dose in the probability of metastatic control.
From all the measures of absorbed dose variability in a given patient, the best correlation with 
the PMADMCP=0.95 was obtained with the range scaled by the minimum absorbed dose (r  =  0.98, 
P  <  0.0001), shown in figure 1(b). When the ratio between the maximum and minimum lesion 
absorbed dose increases by an order of magnitude, the patient mean absorbed dose required to 
eradicate all the lesions increases more than 300% (from 49 Gy to 200 Gy for a ratio of 1–10 
respectively), highlighting the negative effects of absorbed dose variability between lesions.
The metastatic burden reduction model
The metastatic burden reduction curves for the 22 patients are shown in figure  2. The 
PMADMBR=0.5 was 89 Gy (IQR: 83–105 Gy) across all patients. For cut-offs of 0.9 and 0.99 in 
the TCP calculation, PMAD median values of 88 Gy (IQR: 81–106 Gy) and 93 Gy (IQR: 89–
111 Gy) were obtained respectively. An α parameter of 0.25 Gy−1 reduced the PMADMCP=0.95 
by 31% on average, with a median of 61 Gy (IQR: 57–73 Gy).Steep gradients were observed 
for 20 of the 22 patients, which show the potential for a large increase in metastatic burden 
reduction for a small increase in the patient mean absorbed dose delivered. Examination of 
the individual disease distribution for patients 3 and 4, showed that both had the highest vari-
ability in lesion absorbed doses within the patient cohort.
Clinical dosimetry
Our previous study found a total of 379 lesions identified in 22 patients with a median of 11 
lesions (IQR: 3–25) and 227 ml of metastatic tumour burden (IQR: 81–300 ml) per patient. 
The median PMADdelivered across all patients was 19 Gy (IQR: 14–23 Gy) or 3.72 Gy GBq−1 
(IQR: 2.80–4.69 Gy GBq−1). Further details can be found in Denis-Bacelar et al (2017).
Comparison between predicted and delivered absorbed doses
Table 1 and figure 3 summarize the results obtained for the patient cohort studied. The median 
PMADMCP=0.95 was 183 Gy (IQR: 107–247 Gy), the PMADMBR=0.5 was 89 Gy (IQR: 83–105 
Gy) and the median PMADdelivered dose was 19 Gy (IQR: 14–23 Gy).
Figure 1. Relationships between the target dose scaling factor and the minimum 
lesion absorbed dose in a given patient (a), and between the patient mean absorbed 
dose required to eradicate all the lesions (PMADMCP=0.95) and the variability of the 
distribution of absorbed doses delivered to the lesions in a given patient represented by 
the relative difference between minimum and maximum lesion absorbed doses (b). The 
95% confidence bands are shown.
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Discussion
Standard radiobiological models of metastatic control were used to assess the patient-specific 
absorbed doses required to cure all metastatic bone lesions in 22 patients with CRPC meta-
static to bone. A new treatment planning framework was introduced to predict the decrease in 
metastatic burden as a function of the absorbed doses delivered, which could enable person-
alised treatment of bone metastases with the aim of prolonged survival.
The results showed a strong correlation between metastatic control probability and the 
degree of variability of the absorbed doses delivered to multiple lesions, with a median 
PMADMCP=0.95 of 183 Gy. A strong correlation between metastatic control probability and 
minimum lesion absorbed dose was also observed. This indicates the limitations of this model 
alone for treatment planning, since a metastatic burden reduction, rather than complete eradi-
cation of metastases can still be considered a good response to treatment. Application of the 
newly proposed method to the clinical data showed that a median PMADMBR=0.95 of 89 Gy 
would be required to reduce the metastatic tumour burden by 50% in this patient cohort. The 
patient-specific metastatic burden control curves showed that 91% of the patients have a steep 
gradient of the curve, where a large benefit in terms of metastatic burden reduction could be 
achieved by a small increase in the patient mean absorbed dose. In 50% of patients, the patient 
mean absorbed doses required to reduce the metastatic burden by half varied by only 21 Gy, 
whilst differences of 119 Gy were found necessary to eradicate all the lesions. The metastatic 
burden control model could be used to identify patients that would benefit more from treat-
ment. For instance, the results for patient 4 suggest that this treatment may not be effective, 
as it would require very high patient mean absorbed doses to obtain any significant metastatic 
reduction, which would likely result in myelotoxicity. To reduce the risk of toxicity, treatment 
could also be planned according to the lesions that for a given administered activity receive 
high absorbed doses and the lesion(s) with low absorbed doses could be treated with a boost 
dose of external beam radiotherapy.
The predicted absorbed doses for elimination of metastases and metastatic burden reduction 
were considerably higher than the calculated delivered absorbed doses. However, a wide range of 
lesion absorbed doses in patients treated with 186Re-HEDP are available in the literature. Israel et al 
obtained a mean absorbed dose delivered to lesions of 2.1 Gy GBq−1 from 1.532 GBq (Israel et al 
Figure 2. Predicted metastatic burden reduction curves obtained for a cohort of 
22 patients as a function of the patient mean absorbed dose. Patients 3 (*) and 4 (**) 
are indicated.
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Table 1. The patient mean absorbed doses delivered (PMADdelivered) and predicted to 
eradicate all the lesions (PMADMCP=0.95) and to reduce the metastatic tumour burden 
by 50% (PMADMBR=0.5) for the 22 patients. Absorbed doses for MCP values of 0.9 and 
0.99 and TCP values of 0.9 and 0.99 for the MBR  =  0.5 calculation are shown between 
brackets. Absorbed doses for MCP  =  0.95 and MBR  =  0.5 with a radiosensitivity 
parameter α of 0.25 are shown in the last two columns. Patient no.
Patient no.
Patient mean absorbed dose (PMAD) (Gy)
Delivered MCP  =  0.95 MBR  =  0.5
MCP  =  0.95 
(α  =  0.25 Gy−1)
MBR  =  0.5 
(α  =  0.25 Gy−1)
1 8 88 (85–93) 80 (79–90) 60 56
2 22 243 (237–256) 84 (81–87) 166 58
3 15 349 (340–367) 57 (58–64) 239 42
4 30 559 (545–588) 499 (486–500) 383 331
5 22 206 (200–218) 79 (79–85) 140 56
6 11 105 (102–111) 70 (65–72) 72 48
7 31 295 (287–312) 84 (81–89) 201 57
8 20 212 (207–224) 105 (101–110) 145 71
9 25 187 (182–198) 88 (86–93) 128 60
10 18 100 (97–105) 87 (84–92) 68 60
11 19 201 (196–212) 106 (106–111) 138 74
12 15 107 (104–113) 90 (88–91) 73 59
13 24 144 (140–150) 132 (129–141) 99 92
14 9 178 (174–187) 119 (114–122) 122 79
15 23 145 (142–153) 103 (102–109) 99 72
16 10 90 (88–95) 88 (88–93) 62 62
17 18 150 (146–157) 107 (105–112) 103 74
18 25 204 (199–216) 90 (88–95) 140 62
19 22 301 (293–319) 81 (80–86) 205 55
20 17 259 (252–273) 98 (95–104) 177 66
21 16 148 (144–155) 96 (94–99) 101 66
22 12 90 (88–95) 83 (84–90) 62 60
Figure 3. Range of predicted PMADMCP=0.95 and PMADMBR=0.5, and delivered 
PMADdelivered for the 22 patients. The median and inter-quartile range is shown.
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2000) in close agreement with our results. Higher absorbed doses were obtained by Maxon et al, 
with 33 Gy GBq−1 from 1.225 GBq calculated using whole-body planar imaging (Maxon 
et al 1990); and by Andreou et al with 52 Gy GBq−1 from 1.295 GBq (Andreou et al 2010). 
Differences in lesion absorbed doses are likely due not only to the challenges associated with 
the heterogeneity of uptake of bone-seeking radiopharmaceuticals and the difficulty to calculate 
the tumour volume (Bouchet et al 1999, Bouchet and Bolch 1999, Strigari et al 2007), but also 
to the lack of standardization of imaging and dosimetry protocols. Nonetheless, the calculations 
were based on the relative distribution of absorbed doses delivered to multiple lesions in a given 
patient. Therefore the methodology and conclusions drawn from this study are not affected by the 
absolute absorbed doses. Absolute dosimetry would be required to fully understand the biological 
effects of the radiation doses delivered and tailoring the treatment to individual patients (Pouget 
et al 2015). Therefore more efforts are required towards improving the reproducibility and repeat-
ability of the absorbed dose as a biomarker of response in molecular radiotherapy.
This study has some limitations. The relative biological effectiveness (RBE) and radiosensi-
tivity parameters vary for different radionuclides, tissues and activity distributions. The uptake 
of radiopharmaceuticals used for bone metastases highly depends on the osteoblastic activity 
for bone-seeking agents and is highly heterogeneous at the microscopic scale, particularly for 
alpha emitting radionuclides. However the limited resolution of clinical imaging systems only 
allows for macroscopic dosimetry and the assumptions of uniform distribution of activity are 
often made for bone lesion dosimetry (Liepe et al 2003, Baum et al 2016, Pacilio et al 2016). 
The parameters used in the LQ model have been derived from uniformly distributed absorbed 
doses delivered by external beam radiotherapy in prostate cancer patients, as these are not avail-
able for mCRPC and 186Re-HEDP. Different radiobiological parameters would have the effect of 
shifting the absorbed doses required to produce a given effect to lower or higher values although 
the relative positions of the curves would remain constant for all patients. A change in α from 
typical prostate cancer cells (0.15 Gy−1) to less radio-resistant cells (0.25 Gy−1) would reduce 
the patient mean absorbed dose required to kill all the metastases and half the metastatic tumour 
burden by 31–32%. Further clinical studies with pre- and post-therapy imaging would allow the 
validation and refinement of the parameters used in metastatic burden reduction model.
The use of bone-seeking radiopharmaceuticals is rapidly increasing. A survival benefit has 
been observed in patients treated with 223Ra as compared to placebo and 177Lu-DKFZ-617 PSMA 
has been shown to induce remission in a patient with metastatic prostate cancer (Kratochwil et al 
2015). Due to the low number of patients treated and the wide range of absorbed doses reported 
from fixed and/or weight-based administered activities, absorbed dose response relationships 
have not yet been established. Radiation therapy can be an effective treatment for bone pain 
relief and 48 Gy in 3 fractions SBRT treatment in patients with multiple oligometastases, have 
shown promising long-term disease control (Salama et al 2012). An on-going clinical trial is 
investigating the eradication of oligometastases, including bone lesions, in patients with mCRPC 
(NCT02685397). Radiation therapy is typically used in symptomatic and late stages of disease. 
However, implementation of treatment early in the course of the disease may increase quality 
of life and reduce overall metastatic tumour burden; in turn, delaying disease progression and 
improving long-term survival. This could be of particular relevance for molecular radiotherapy, 
where radiation is targeted to specific molecular sites and toxicity is limited.
Conclusion
The metastatic burden reduction model proposed in this study offers the potential to provide 
individualised treatment and could be used as a patient selection tool by relating potential 
benefit and toxicity. Metastatic burden reduction curves could be predicted from pre-therapy 
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imaging or from therapy imaging, which would enable adaptive treatment planning for 
repeated administrations. This simple tool has the potential to inform patient management by 
individualising treatment in patients with multiple tumours or metastatic disease undergoing 
molecular radiotherapy. Future studies of treatment response will allow validation and refine-
ment of the model.
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